Source: https://www.safeaccessnow.org/trump_administration_s_only_role_in_new_hemp_law_nears_deadline
Overview
Americans for Safe Access warns that patients who turned to hemp-derived CBD due to cost, access deserts, and limited state medical programs may face sudden loss of access when the Nov ban hits. The FDA’s cannabinoid deadline doesn’t establish clinical pathways, insurance coverage, or patient safeguards. Despite the Dec 2025 Executive Order acknowledging flaws, the Administration can’t revise the Controlled Substances Act. State program improvements are patients’ best hope.
Clinical Perspective
🔹 THE PATIENTS NO ONE’S TALKING ABOUT
Americans for Safe Access warns: millions who rely on hemp CBD face ‘abrupt disruptions in care.’
💊 Many chose hemp CBD because it was more affordable
🔹 Others live in access deserts with no dispensaries
🌿 Limited state medical programs pushed them to hemp
⚖️ New law has NO clinical pathways
🔹 NO insurance coverage provisions
⚠️ NO patient safeguards
The Executive Order acknowledges flaws—but can’t fix what only Congress can change.
State program improvements are patients’ best hope. Time is running out.
Have thoughts on this? Share it: